Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 51

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Summary

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2017, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection and Liver Transplant Rejection.

Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects

- The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview 6
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 14
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc 18
Hookipa Biotech AG 18
Immunomic Therapeutics Inc 18
Vakzine Projekt Management GmbH 19
Vaximm AG 19
VBI Vaccines Inc 20
Vical Inc 20
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 21
ASP-0113 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CyMVectin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HB-101 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PepVax - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Triplex - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VBI-1901 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VPM-2001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
VXM-65 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products 38
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 39
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones 40
Featured News & Press Releases 40
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 40
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 40
May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 41
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 41
Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections 42
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 42
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood 43
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 44
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 44
Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 45
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 45
Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine 46
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 46
Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 47
Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Astellas Pharma Inc, H2 2017 18
Pipeline by Hookipa Biotech AG, H2 2017 18
Pipeline by Immunomic Therapeutics Inc, H2 2017 19
Pipeline by Vakzine Projekt Management GmbH, H2 2017 19
Pipeline by Vaximm AG, H2 2017 19
Pipeline by VBI Vaccines Inc, H2 2017 20
Pipeline by Vical Inc, H2 2017 20
Dormant Projects, H2 2017 38
Discontinued Products, H2 2017 39

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16
  • Global DNA Forensic Market Research Report 2018
    Published: 19-Jun-2018        Price: US 2900 Onwards        Pages: 91
    This report studies the global DNA Forensic market status and forecast, categorizes the global DNA Forensic market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa). DNA forensics is a branch of forensic science that focuses on the use of genetic material in criminal investigation to an......
  • Global Somatostatin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin. Scope of the Report: This report focuses on the Somatostatin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East an......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Somatostatin Market 2018, Forecast to 2023
    Published: 19-Jun-2018        Price: US 4880 Onwards        Pages: 151
    Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin. Scope of the Report: This report focuses on the Somatostatin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East an......
  • 2015-2023 World Biological Safety Testing Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 16-Jun-2018        Price: US 2800 Onwards        Pages: 112
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • Global Procalcitonin Antibody Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Procalcitonin Antibody Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 150
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 132
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 136
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) - Global Forecast to 2023
    Published: 15-Jun-2018        Price: US 5650 Onwards        Pages: 124
    “The global transfer membrane market projected to grow at a CAGR of 1.5%.” The global transfer membrane market is projected to reach 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5%. Factors such as increasing financial support from public and private funding sources for life science research, high prevalence of target diseases across the globe, and increasing research and development expenditure by pharmaceutical and biotechnology ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs